Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Rigel Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject must have had a diagnosis of primary or secondary warm antibody AIHA.
\- Must have failed at least 1 prior treatment regimen for AIHA.
You may not be if
Subject with cold antibody AIHA, cold agglutinin syndrome, mixed type AIHA, or paroxysmal cold hemoglobinuria.
Subject with a platelet count of \< 30,000/μL.
Subject has AIHA secondary to autoimmune disease, including systemic lupus erythematosis (SLE), or lymphoid malignancy and the underlying disease is not stable or is not well-controlled on current therapy.
Subject has uncontrolled or poorly controlled hypertension, defined as systolic blood pressure ≥ 130 mmHg, or diastolic blood pressure ≥ 80 mmHg.
Clareo Health | A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)
